Genetic Engineering & Biotechnology News

FEB15 2018

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 0 of 31

The $1,000 genome—or even the $100 genome—could be closer to becom- ing a reality than ever before. Thanks in large part to the prowess of Illumina, the cost of DNA sequencing has decreased by four orders of magnitude during the period 2007–2012. 1 But, in the past few years, the rate at which the cost of sequencing has been dropping has plateaued. Competition has also slowed, experts say. 1,2 For the past decade, since the acqui- sition of the British firm Solexa in 2006, Illumina has been the dominant player in the market. Illumina claims to be the platform that has delivered the $1,000 genome and produced more than 90% of the world's genome sequence data. Over the years, Illumina has fought off com- petition from Life Technologies and Ion Torrent (Thermo Fisher Scientific), 454 Life Sciences (Roche), and other companies For example, in clinical applications, proteomic patterns may sup- port predictions about health and disease. Proteomic analyses—wheth- er they are performed on samples consisting of cells, tissues, or body fluids—may yield trustworthy visions, including clear, comprehensive views of biological systems, as well as dependable representations of large patient cohorts. The mainstream proteomic approach, termed bottom-up or shotgun proteomics, employs mass spectrometry (MS) technologies. These technol- ogies continue to evolve as investigators seek more speed and sensitivity in their proteomic analyses, as well as the ability to carry out multiplex assays. MS advances relevant to translational research and clinical prac- tice were discussed at the Twelfth International Symposium on Mass Spectrometry in the Health and Life Sciences: Molecular and Cellular Proteomics. This event, which was organized by the Mass Spectrom- etry Facility of the University of California, San Francisco, emphasized chemical proteomics, methodologies enabling new insights into biology, and emerging challenges in medicine and biology. Several presenters noted that clinical proteomics is on the rise be- cause MS can create unbiased, real-time snapshots of the cell proteome and identify pathways of therapeutic resistance. Other presenters pre- dicted that proteomics would gain new pow- ers through microfluidics and nanotechnology. see page 12 see page 22 Randi Hernandez Intense competition in the genomic-sequencing space continues, but not at a level that once fueled the field. Could progress in sequencing tools and research overseas help democratiza- tion of sequencing in the United States? (Part I of a two-part series) Kathy Liszewski Like the bubbling contents of a cauldron, the proteome may bring about toil and trouble instead of clear and reliable prophecy. The proteome, however, is no mere witches' brew of proteins. When the proteome is subjected to analysis, it may reveal meaningful patterns. Sequencing Within Reach Illustration by Cristina Spanò Next-Gen Sequencing Market * 2017 $9.6 billion *Source: Reportlinker 2022 $12.45 billion (CAGR 20.5%) I N T H I S I S S U E The Scoop A Tiny Heartbeat Away from New Cardiac Meds 6 Life's Code Accepts New Characters 16 New Methods Improve Ab Engineering 10 Single-Use Avoids a Midlife Crisis 18 February 15, 2018 Proteomics Conjures Up Clinical Insights

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - FEB15 2018